Journal of Adolescent Health
Volume 50, Issue 2 , Pages 110-131, February 2012

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

  • Sarah M. Tiggelaar

      Affiliations

    • Department of Cancer Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, P. R. China
    • Vanderbilt University, School of Medicine, Nashville, Tennessee
    • S.M. Tiggelaar and M.J. Lin contributed equally and are co-first authors.
    • ,
  • Margaret J. Lin, M.D.

      Affiliations

    • Department of Cancer Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, P. R. China
    • Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Maryland
    • S.M. Tiggelaar and M.J. Lin contributed equally and are co-first authors.
    • ,
  • Raphael P. Viscidi, M.D.

      Affiliations

    • Department of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, Maryland
    • ,
  • Jia Ji, Ph.D.

      Affiliations

    • Department of Cancer Epidemiology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, P. R. China
    • Division of Pharmaceutics, College of Pharmacy, Ohio State University, Columbus, Ohio
    • ,
  • Jennifer S. Smith, Ph.D., M.P.H.

      Affiliations

    • Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina
    • Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina
    • Corresponding Author InformationAddress correspondence to: Jennifer S. Smith, Ph.D., M.P.H., Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, Campus Box 7435, Chapel Hill, NC 27599

Received 3 May 2011; accepted 15 October 2011.

Abstract 

Purpose

Global data on human papillomavirus (HPV) serological and deoxyribonucleic acid (DNA) prevalence are essential to optimize HPV prophylactic vaccination strategies.

Methods

We conducted a global review of age-specific HPV antibody and studies with both antibody and DNA prevalence for HPV-16, −18, −6, and −11.

Results

One hundred seventeen studies were included; participants' ages ranged from several hours to >90 years. HPV-16 seroprevalence was generally higher in Africa, Central and South America, and North America, more prevalent among women than among men, and peaked around ages 25–40 years. HPV-18 seroprevalence was generally lower than HPV-16 with a later age peak. Data were limited for HPV-6 and −11, both of which peaked at ages similar to HPV-18. Among 9–26-year-old females, HPV-16 seroprevalence ranged from 0%–31% in North America, 21%–30% in Africa, 0%–23% in Asia/Australia, 0%–33% in Europe, and 13%–43% in Central and South America. HPV-16/-18 DNA prevalence peaked 10–15 years before corresponding HPV-16/-18 antibody prevalence.

Conclusions

Females within the HPV vaccine-eligible age-group (9–26 years) had a range of dual HPV-16 DNA and serology negativity from 81%–87%, whereas 90%–98% were HPV-16 DNA negative. Serology and DNA data are lacking worldwide for females younger than age 15 years, the prime target group for vaccination.

Keywords:  Global , Human papillomavirus , Serology , DNA , Prevalence , Immunology , Antibodies

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 J.S. Smith has received research grants, honoraria, or consultancy fees from GSK or Merck within the last 5 years. No other authors on this manuscript have any conflicts of interest related to this work. A GlaxoSmithKline representative read the article before submission for publication but had no role in study design, analysis of data, or the decision to submit the manuscript for publication. The first draft of the manuscript was jointly written by J. Ji, M.J. Lin, and S.M. Tiggelaar.

PII: S1054-139X(11)00354-5

doi:10.1016/j.jadohealth.2011.10.010

Journal of Adolescent Health
Volume 50, Issue 2 , Pages 110-131, February 2012

Article Tools

* Image Usage & Resolution